MANY MINDEDRadiopharma consolidates: Curium agrees to buy Lantheus
Curium and Lantheus announced a definitive merger agreement on 3 August 2026, under which Lantheus will merge with a wholly owned subsidiary of Curium US. Shareholders receive $102.50 per share in cash at closing, plus contingent value rights worth up to a further $12.00 per share tied to commercial milestones running through 2030. Together that puts the transaction at up to approximately $8.0 billion. Curium is backed by CapVest Partners. The companies expect to close in the first half of 2027, subject to Lantheus shareholder approval.
The stated logic is coverage across the field rather than scale alone. Lantheus brings radiodiagnostics; Curium brings oncology, neurology and cardiology products. The combined business would span both the diagnostic and therapeutic halves of radiopharmaceuticals with distribution described as reaching more than 70 countries.
Radiopharmaceuticals are one of the few areas of medicine where the supply chain is the constraint as much as the science: the isotopes decay, so they cannot be stockpiled, and getting a dose to a patient is a logistics problem with a clock on it. A network that already reaches 70 countries is the asset here. Whether that translates into wider access or simply a stronger negotiating position is not something the announcement addresses, and nothing in it commits to a price. Consolidation can cut duplicated distribution cost or it can remove a competitor; this one has not yet shown which.
Source: Fierce Biotech